Showing 691-700 of 3737 results for "".
Physician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-steven-r-feldman-md-phd/20779/Amid roadblocks, opportunities exist to improve adherence among dermatology patientsPhysician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-steven-r-feldman-md-phd/20541/The new thinking on improving adherence in dermatology.Approval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by healWomen in Dermatology: Melissa Kanchanapoomi Levin, MD
https://practicaldermatology.com/topics/practice-management/women-in-dermatology-melissa-kanchanapoomi-levin-md/23063/Benchside Dispatches: Pruritus
https://practicaldermatology.com/topics/practice-management/benchside-dispatches-pruritus/20926/An interview with Gil Yosipovitch, MDWomen in Dermatology: Amy Brodsky, MD, FAAD
https://practicaldermatology.com/topics/practice-management/women-in-dermatology-amy-brodsky-md-faad/23470/The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Effector Cell Response Inhibitors
https://practicaldermatology.com/videos/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urPhysician Spotlight: Robert S. Kirsner, MD, PhD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-robert-s-kirsner-md-phd-faad/20319/It's time to get wound up about wound care.Physician Spotlight: Nehal N. Mehta, MD, MSCE, FAHA
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-nehal-n-mehta-md-msce-faha/20442/Psoriasis comorbidities: Is extinguishing systemic inflammation the solution?